Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.
About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...
Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is ...
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.